Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis...

Area of Science:

• Nephrology
• Pharmacology
• Clinical Trials

Background:

• Phosphate binders (PBs) often present a high pill burden for patients.
• Tenapanor offers a novel therapeutic approach by inhibiting intestinal phosphate absorption.
• Managing hyperphosphatemia is crucial for patients with chronic kidney disease.

Purpose of the Study:

• To evaluate the long-term safety and tolerability of tenapanor in hemodialysis patients.
• To assess the efficacy of tenapanor in reducing the overall daily pill burden of phosphate binders.
• To monitor serum phosphorus levels during extended tenapanor treatment.

Main Methods:

• A multicenter, open-label, single-arm, phase 3 study.
• Administered tenapanor (5-30 mg twice daily) to hemodialysis patients with elevated serum phosphorus.
• Patients could switch from existing phosphate binders to tenapanor.

Main Results:

• 77.5% of patients achieved a ≥30% reduction in daily pill count.
• Diarrhea was the most common adverse event (63.7%), mostly mild.
• Serum phosphorus levels remained stable within the target range (3.5-6.0 mg/dl).

Conclusions:

• Tenapanor demonstrates long-term safety and tolerability in hemodialysis patients.
• Tenapanor effectively reduces or eliminates the need for traditional phosphate binders.
• This novel agent offers a promising strategy for managing hyperphosphatemia and improving patient adherence.